Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
BioAge Labs, Inc. (BIOA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.54-6.89%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BIOA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
improve net income towards profitability | BioAge Labs aims to improve cash flow and net income from current losses. | Under Pressure | net income loss widens or EPS falls below -0.52 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
BIOA is a speculative clinical-stage biotech, with its longer-term case tied to clinical progress rather than established earnings. The thesis is on watch: management priorities are progressing, but recent financial performance is weak and the risk label has risen to high.
The valuation model shows BIOA at a premium to peers, with optionality as the main valuation driver. Its expectations gap is strongly negative, which suggests expectations are demanding relative to the model, though confidence in that estimate is low; the priced-in label is justified and no fragility gates fired.
In the near term, BIOA is likely to remain loss-making as R&D spending rises, while collaboration revenue has grown over time but eased from the prior quarter. Management has advanced BGE-102, including the first participant dosed in the QUELL-CV Phase 2 trial, and estimates current cash can fund operations through 2029. Near-term execution risk remains high, with a meaningful chance of a miss and a possible guidance cut to watch for.
The multi-year thesis hinges on clinical progress and useful data from BGE-102, alongside keeping enough cash to fund development. A guidance cut or further weakening in jobs data could add pressure to the business outlook, while strong results and higher guidance from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, BIOA remains a high-risk clinical development story with stated priorities on track, but weak recent performance and demanding expectations leave the thesis under watch. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Management targets positive cash flow and better net income, with revenue growth from new products. |
| Under Pressure |
| cash from operating activities remains negative throughout FY26 |
Cash from operations: $-19.26M FY2026-Q2; GAAP. Published target: >= $0 cash from operating activities. Annual target cannot be compared with a quarterly or TTM observation. Aug 5, 2026-19,260,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
increase revenue through new products and market expansion | Management targets positive cash flow and better net income, with revenue growth from new products. | Broken | revenue declines below $2.77M per quarter over next year | Revenue: $2.451M FY2026-Q2; GAAP. Published target: revenue grows or stabilizes above $2.77M per quarter. Target period is not explicitly aligned with this observation. Aug 5, 20262,451,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.04 → $-2.26 · observed estimates
$0.04B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.04 | $35,951,100 | 7 / 10 |
| 2026-07-25 | $-2.04 | $35,951,100 | 7 / 10 |
| 2026-07-26 | $-2.04 | $35,951,100 | 7 / 10 |
| 2026-07-27 | $-1.86 | $35,951,730 | 6 / 7 |
| 2026-07-28 | $-2.04 | $35,951,100 | 7 / 10 |
| 2026-07-29 | $-2.04 | $35,951,100 | 7 / 10 |
| 2026-07-30 | $-2.04 | $35,951,100 | 7 / 10 |
| 2026-07-31 | $-2.04 | $35,951,100 | 7 / 10 |
| 2026-08-01 | $-2.04 | $35,951,100 | 7 / 10 |
| 2026-08-02 | $-2.45 | $17,831,700 | 7 / 10 |
| 2026-08-03 | $-2.45 | $17,831,700 | 7 / 10 |
| 2026-08-04 | $-2.45 | $17,831,700 | 7 / 10 |
| 2026-08-05 | $-2.45 | $17,831,700 | 7 / 10 |
| 2026-08-06 | $-2.45 | $17,831,700 | 7 / 10 |
| 2026-08-07 | $-2.09 | $17,832,860 | 6 / 7 |
| 2026-08-08 | $-2.41 | $17,299,440 | 7 / 9 |
| 2026-08-09 | $-2.41 | $17,299,440 | 7 / 9 |
| 2026-08-10 | $-2.41 | $17,299,440 | 7 / 9 |
| 2026-08-11 | $-2.36 | $15,672,900 | 7 / 10 |
| 2026-08-12 | $-2.36 | $15,672,900 | 7 / 10 |
| 2026-08-13 | $-2.36 | $15,672,900 | 7 / 10 |
| 2026-08-14 | $-2.09 | $17,832,860 | 6 / 7 |
| 2026-08-15 | $-2.09 | $17,832,860 | 6 / 7 |
| 2026-08-16 | $-2.09 | $17,832,860 | 6 / 7 |
| 2026-08-17 | $-2.09 | $17,832,860 | 6 / 7 |
| 2026-08-18 | $-2.09 | $17,832,860 | 6 / 7 |
| 2026-08-19 | $-2.09 | $17,832,860 | 6 / 7 |
| 2026-08-20 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-21 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-22 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-23 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-24 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-25 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-26 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-27 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-28 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-29 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-30 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-08-31 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-01 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-02 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-03 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-04 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-05 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-06 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-07 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-08 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-09 | $-2.14 | $15,671,000 | 6 / 7 |
| 2026-09-10 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-11 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-12 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-13 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-14 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-15 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-16 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-17 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-18 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-19 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-20 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-21 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-22 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-23 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-24 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-25 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-26 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-27 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-28 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-29 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-09-30 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-01 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-02 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-03 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-04 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-05 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-06 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-07 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-08 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-09 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-10 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-11 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-12 | $-2.17 | $15,671,000 | 6 / 7 |
| 2026-10-13 | $-2.24 | $14,882,727 | 7 / 8 |
| 2026-10-14 | $-2.27 | $14,882,727 | 7 / 8 |
| 2026-10-15 | $-2.27 | $14,882,727 | 7 / 8 |
| 2026-10-16 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-17 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-18 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-19 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-20 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-21 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-22 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-23 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-24 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-25 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-26 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-27 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-28 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-29 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-30 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-10-31 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-11-01 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-11-02 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-11-03 | $-2.26 | $14,882,727 | 7 / 8 |
| 2026-11-04 | $-2.26 | $14,882,727 | 7 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.